RE: $BMY30 Oct 2025 22:13
“Based on the leading indicators that we’re seeing, Cobenfy is going to deliver continued, steady growth in schizophrenia, and longer-term growth is going to be fueled by additional indications,” Lenkowsky said, adding that “we are confident that Cobenfy will be a big drug over time.”
https://www.fiercepharma.com/pharma/cobenfy-delivers-ok-debut-year-bms-works-ease-nerves-alzheimers-psychosis-trial